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Dengue: 2.5 billion People at Risk

With the recent outbreak of Zika virus in Central and South America, there has been
an increased demand for vaccines around the world for both zika and dengue virus.
Due to a combination of high environmental temperatures and poor cold-storage
capabilities in developing countries, it is often difficult for a live-attenuated vaccine to
be shipped and maintained. In order to preserve and stabilize vaccines at refrigerated
temperatures so that they can be easily shipped and stored, lyophilization (freezedrying) can be explored as a possible solution. A successful lyophilization process will
ensure an extended product shelf life, improve virus stability, and result in less
expensive shipping. Furthermore, expensive storage freezers, which are not often
found in underdeveloped areas of the world that are most in need of lifesaving
vaccines, will not be required.

 390 million annual infections
 96 million infections are clinically apparent
 Endemic in over 100 countries
 Skilled medical care reduces deaths to <1%

While working as a student intern at the National Institutes of Health (NIH) in
Bethesda, Maryland within the National Institute of Allergy and Infectious Diseases
(NIAID), experiments were conducted with a variety of lyophilization conditions.
Scientific articles describing lyophilization techniques were studied in order to
determine potential reagents and formulation conditions. A new VirTis® Lyophilizer
(SP Scientific, Warminster, PA) was set-up and programmed. Successful
lyophilization is dependent on several variables including temperature, pressure, and
composition of the fluid excipient. Proper conditions and formulation of the excipient
will result in a lyophilization “cake” that remains solid, yet fluffy, and is easily
rehydrated. A variety of candidate excipients were formulated, lyophilized, and
examined for suitability of the cake. Promising excipient mixtures were subsequently
added to a live attenuated dengue virus vaccine candidate and lyophilized. Control
studies were performed by comparing lyophilized samples to equivalent samples that
were stored at -80oC. Following resuspension of the lyophilized material, both the
frozen and previously dried samples were serially diluted and inoculated onto Vero
[African green monkey kidney] cell monolayers in 24-well plates. After five days
incubation, the cell monolayers were immunostained using antibodies and TrueBlue
substrate. Virus-infected cells (plaques) appeared dark blue and were counted to
determine the infectious titer of the virus. The titers of some lyophilized virus
formulations equaled or exceeded titer levels in samples that were frozen at -80oC,
indicating that a desirable level of thermostability was achieved. A user manual was
also created to teach NIAID scientists how to use the lyophilizer instrument and
create their own samples for ongoing research. While results obtained in this pilot
study appear promising in a laboratory setting, future studies are needed to
demonstrate successful thermo-stability in the field especially under challenging
shipping conditions. It is expected that important Zika and dengue vaccines under
development for future use can benefit from the work performed here.

Why use lyophilization?
•
•
•
•
•

Lyophilized products are lightweight and solid
Does not require an ultra cold environment (-80oC) for storage
Virus morphology and infectivity can be stabilized
Product shelf life can be improved
Less expensive shipping to tropical countries

The Lyophilization Process
Source: Biopharma Process Systems

Abstract

Image From: WHO; Hotez et al., 2009

FREEZE
The samples must be frozen completely into a solid

VACUUM
The air pressure will decrease until a vacuum has been reached

PRIMARY DRYING

SECONDARY DRYING
The temperatures increase above room temperature and all the remaining water is
removed

STOPPERING & VACUUM RELEASE
The stoppering mechanism presses the lids down to seal the vials (while in a
vacuum). The air pressure increases as the chamber is backfilled with an inert gas.

Source: lyophilizedproducts.com

The temperature of the shelf slowly increases as water vapor escapes and
collects on the condenser coils. This is the longest step in the entire process

Graphic by Marshall Butler
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Results: Testing Preservation of a Dengue
Virus Live Vaccine Candidate

A total of 70 excipient formulations were tested for suitability of the cake and a
subset were down selected for further evaluation. A live attenuated dengue virus
vaccine candidate, rDEN4Δ30, was combined with a number of various excipients
and either lyophilized or stored at -80oC. Lyophilized virus samples were then
resuspended, serially diluted, and inoculated into Vero cells. After incubation, the
cells were stained with antibodies and TrueBlue substrate, and virus titers were
calculated. The data from several excipients is included in the graph below.

Preparing Successful Samples
–
–
–
–
–

Buffers and pH adjusters
Bulking agents
Stabilizers (sugars)
Stabilizers (biological)
Tonicity modifiers

Preparing a “Recipe” for your Lyophilizer

Examples

- Tris, Citrate buffers
- Mannitol, Sucrose, Dextran
- Trehalose, Sucrose, Lactose, Sorbitol
- Serum (FBS), Albumin
- Glycerol, Sodium Chloride

• Only certain types of excipients lyophilize well

– Chemicals with the following characteristics are known to not be as
successful
•
•
•
•
•

Phosphate Buffered Saline (PBS)
Products rich in oil
Those with high sugar content (such as Sucrose Phosphate Glutamate [SPG])
Those with high salt content
Products that form an impervious skin (water unable to escape)

Photos taken by Marshall Butler

Excipient:
SPG 5X +
Mannitol 20%

Ideal Product
Excipient:
FBS 25%

VirTis® Freeze-Dryer by SP Scientific

Looking Inside Lyophilized Products

Examples of Finished Products

Collapsed
Product

A “recipe”, composed of several steps, can be
programmed for a freeze-dryer machine to allow the
entire lyophilization process to run automatically and
continuously. Every recipe consists of multiple steps
within the following cycles:
•Thermal Treatment
•Freezing
•Primary Drying
•Secondary Drying/ post-heat settings

Photo by SP Industries

• Classifications of Excipients

Photos from: Lyophilization of Pharmaceutical and Biological Products, Third Edition

(A)
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Fundamentals of the Lyophilization Process

(B)

(A) Scanning electron micrograph of the upper surface of a freeze-dried pellet
showing a membrane like “skin” with elongated “vents” for the escape of water
vapor. (B) Scanning electron micrograph of the inside middle part of a freeze-dried
“cake” showing the extremely porous material resulting from the sublimation of icecrystals.

A recipe is usually specific to the
type/design of freeze-dryer, size of the
machine, and number of samples that are
being lyophilized. A freeze-dryer containing
a dozen samples may only require a recipe
with a duration of 20 hours, but a large
industrial freeze-drier for pharmaceutical
companies may require a recipe that takes
over 72 hours to complete.
A successful recipe will usually have
multiple elements including:
•Slow temperature changes (rapid changes
can cause the product to collapse)
•A complete solid freeze of the product
before the freeze-dryer chamber begins
establishing a vacuum
•Temperature settings that never exceed
the glass transition temperature (collapse
temperature) during the primary drying
cycle

Conclusions

• When combined with different excipients, the dengue vaccine
candidate was found to have varying titers
• After lyophilization, certain excipient/virus mixtures produced higher
titers than the same mixtures which were kept frozen at -80oC
• The excipients that maintained the highest titers contained
Trehalose, Pluronic® F-127, and Dextran
• These experiments demonstrate lyophilization is a viable approach
for stabilization and storage of vaccines, which may enable future
refrigerated shipments to areas of the world where ultra-low
temperature storage is not readily available
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